Prescribing information

 

________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

Inclisiran is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:

  • in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or
  • alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.1

Explore our growing repository of resources designed to provide useful information on inclisiran and other relevant topics for healthcare professionals treating patients with ASCVD.

 

Inclisiran is not yet available to prescribe in the UK.

Inclisiran HCP resources

Inclisiran HCP resources-Image preview of a slide with text next to it saying 'ORION-10 AND ORION-11 CLINICAL FACT SHEET'. Blue box with text: Download.

ORION-10 AND ORION-11 CLINICAL FACT SHEET

A downloadable summary of ORION-10 and ORION-11 trials for quick reference and understanding.

Download

 
 

INCLISIRAN MOA VIDEO

A video displaying the mechanism of action of inclisiran, the first and only siRNA LDL-C-lowering therapy.1-3

 
 
 
 
 

ELEVATED LDL-C: THE IMPORTANCE OF EARLY INTERVENTION

A short animation highlighting the consequences of long-term exposure to persistently elevated LDL-C.

 

 

As the site grows, we will be adding lots of new content. SIGN UP to receive our email communications and make sure you don’t miss the latest updates.

 

ASCVD, atherosclerotic cardiovascular disease; HCP, healthcare professional; LDL-C, low-density lipoprotein cholesterol; MOA, mechanism of action; siRNA, small interfering ribonucleic acid.

References

  1. Leqvio® Summary of Product Characteristics.
  2. Stoekenbroek RM et al. Future Cardiol 2018;14(6):433–442. 

  3. Klinovski M et al. CADTH Issues in Emerging Health Technologies, 2019. Canadian Agency for Drugs and Technologies in Health. 

UK | April 2021 | 112959
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]